Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer
Yitong Li,Ruihang Zhang,Zhen Xu,Zhicheng Wang
DOI: https://doi.org/10.2147/IJN.S349426
IF: 7.033
2022-02-26
International Journal of Nanomedicine
Abstract:Yitong Li, 1 Ruihang Zhang, 2 Zhen Xu, 1 Zhicheng Wang 1 1 NHC Key Laboratory of Radiobiology (Jilin University), School of Public Health, Jilin University, Changchun, 130021, Jilin, People's Republic of China; 2 Second Clinical Medical College, Henan University of Traditional Chinese Medicine, Zhengzhou, 450052, Henan, People's Republic of China Correspondence: Zhicheng Wang, NHC Key Laboratory of Radiobiology (Jilin University), School of Public Health, Jilin University, 1163 Xinmin Street, Changchun, 130021, Jilin, People's Republic of China, Tel +86 13843131059, Fax +86 431185619443, Email The mortality rate of liver cancer is gradually increasing worldwide due to the increasing risk factors such as fatty liver, diabetes, and alcoholic cirrhosis. The diagnostic methods of liver cancer include ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI), among others. The treatment of liver cancer includes surgical resection, transplantation, ablation, and chemoembolization; however, treatment still faces multiple challenges due to its insidious development, high rate of recurrence after surgical resection, and high failure rate of transplantation. The emergence of liposomes has provided new insights into the treatment of liver cancer. Due to their excellent carrier properties and maneuverability, liposomes can be used to perform a variety of functions such as aiding in imaging diagnoses, combinatorial therapies, and integrating disease diagnosis and treatment. In this paper, we further discuss such advantages. Graphical Keywords: liver targeting, nanotherapeutics, nanocarriers, multimodal imaging, nanomedicine, diagnostic treatment integration Graphical Liver cancer is the leading cause of cancer death, with an annual increase in incidence. 1 Hepatocellular carcinoma (HCC) represents ~90% of primary liver cancers and constitutes a major global health problem. 2 The risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol addiction, metabolic liver disease (particularly nonalcoholic fatty liver disease) and exposure to dietary toxins, such as aflatoxins and aristolochic acid. 3 The staging of HCC is particularly complicated due to the varying presence of concomitant liver dysfunction. The staging of HCC is generally performed using the Okuda staging system, the Cancer of the Liver Italian Program, the Hong Kong Liver Cancer (HKLC) staging system, and the Barcelona Clinic Liver Cancer (BCLC) staging system, which is the most popular. 4 The current approach to HCC treatment depends on the stage at which the patient is diagnosed. 5 The BCLC staging system recommends that only patients classified as BCLC stage 0 or A be administered surgical resection or liver transplantation. In contrast, patients with BCLC stage B and BCLC stage C are recommended for transarterial chemoembolization (TACE) or transarterial radioembolization (TARE). 6 BCLC stage D, known as the end-stage, is currently treated symptomatically using the best supportive care. 5 Although several studies have demonstrated the rationality of the BCLC system, the BCLC standard is also controversial. A meta-analysis of 2619 Asian HCC patients showed that surgical resection provided better overall survival than TACE in BCLC stage B patients, without any significant increase in postoperative complications or 30-day mortality. 7 The Derwent Innovation Platform collects data from a global sample of patents related to HCC treatment technologies, which show future trends in the treatment of HCC. The platform explores novel molecular therapies, localized and visible local therapies, and combinations of immunotherapy with targeted therapies or other conventional treatments. 8 In addition to surgical resection, liver transplantation, and percutaneous ablation, clinical studies have also recently evaluated liposomes and lipid nanoparticles as therapies for liver cancer. Liposomes are spontaneously-forming and spherical fragments consisting of a lipid bilayer and a hydrophilic core. 9 Research on liposome technology has progressed from conventional vesicles (first-generation liposomes) to second-generation liposomes, in which long-circulating liposomes are obtained by modulating the lipid composition, size, and charge of the vesicle. 10 Second-generation liposomes have been designed as tumor-targeting drug delivery vehicles for the precise delivery of active drugs into tumor cells. 11 The unique properties of liposomes, including their biocompatibility, biodegradability, amphiphilic nature, low toxicity, non-ionicity, sustained release, and ability to be actively targeted, have provided many biomedi -Abstract Truncated-